Journal Options Oncology - Volume 2, Issue 1
Course Directors: Robert S. Mocharnuk, MD
Volume 2, Issue 1 Articles
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
Attal M, Harousseau JL, Leyvraz S, et al. Blood. 2006;108:3289-3294. Capsule Summary | Expert Commentary | Abstract | Slides
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
Chanan-Khan A, Miller KC, Musial L, et al. J Clin Oncol. 2006;24:5343-5349. Capsule Summary | Expert Commentary | Abstract | Slides
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI, Kouroukis CT, White D, et al. J Clin Oncol. 2007;25:1570-1575. Capsule Summary | Expert Commentary | Abstract | Slides
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Forstpointner R, Unterhalt M, Dreyling M, et al. Blood. 2006;108:4003-4008. Capsule Summary | Expert Commentary | Abstract | Slides
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
Harousseau JL, Attal M, Leleu X, et al. Haematologica. 2006;91:1498-1505. Capsule Summary | Expert Commentary | Abstract | Slides
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 Trial.
Moorman AV, Harrison CJ, Buck GA, et al. Blood. 2007;109:3189-3197. Capsule Summary | Expert Commentary | Abstract | Slides
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S, Moore JO, Boyd TE, et al. J Clin Oncol. 2007;25:1114-1120. Capsule Summary | Expert Commentary | Abstract | Slides
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
Walker R, Barlogie B, Haessler J, et al. J Clin Oncol. 2007;25:1121-1128. Capsule Summary | Expert Commentary | Abstract | Slides
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
Xicoy B, Ribera JM, Miralles P, et al. Haematologica. 2007;92:191-198. Capsule Summary | Expert Commentary | Abstract | Slides
Therapeutic results in patients with relapsed diffuse large B cell non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation.
Ferrara F, Viola A, Copia C, et al. Hematol Oncol. 2006;24:73-77. Capsule Summary | Expert Commentary | Abstract | Slides
|
Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC.
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
Volume 2, Issue 1
Collection
Journal Options Oncology: Hematologic Malignancies, Volume 2, Issue 1
Course Director: Robert S. Mocharnuk, MD
  
- Bruce D. Cheson, MD
- Bruce J. Dezube, MD
- Frederick B. Hagemeister, MD
|
  
- Sagar Lonial, MD
- Craig H. Moskowitz, MD
- Liron Pantanowitz, MD
|
  
- Noopur Raje, MD
- Deborah A. Thomas, MD
- Steven P. Treon, MD, MA, PhD
|
|